Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2

Circulation Research

Volumn 95, Issue 11, 2004, Pages 1118-1124

  Ohtsubo, Toshio ^a   Rovira, Ilsa I ^a   Starost, Matthew F ^b   Liu, Chengyu ^a   Finkel, Toren ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclooxygenase; Kidney

Indexed keywords

CYCLOOXYGENASE 2; URIC ACID; XANTHINE OXIDASE;

ANIMAL CELL; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; ENZYME INDUCTION; ENZYME REGULATION; FAILURE TO THRIVE; IN VITRO STUDY; KIDNEY DEVELOPMENT; KIDNEY DYSPLASIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; URIC ACID BLOOD LEVEL; WILD TYPE;

ANIMALS; BLOOD UREA NITROGEN; CYCLOOXYGENASE 2; DISEASE PROGRESSION; ENZYME INDUCTION; FEMALE; GENES, LETHAL; GENETIC HETEROGENEITY; HYPERTENSION; INFLAMMATION; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, KNOCKOUT; NIH 3T3 CELLS; PHENOTYPE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; URIC ACID; XANTHINE OXIDASE;

EID: 9344250533     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000149571.96304.36     Document Type: Article

References (42)

1. Schardinger RZ. Untersuch Nahrungs Genussmittel 1902;5:1113-1121.
2. Hille R, Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. FASEB J. 1995;9:995-1003.
3. Harrison R. Structure and function of xanthine oxidoreductase: where are we now. Free Radic Bol Med. 2002;33:774-797.
4. Garattini E, Mendel R, Romao MJ, Wright R, Terao M. Mammalian molybo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J. 2003;372:15-32.
5. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: From urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002;9:161-175.
6. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma. 2003:3:225-232.
7. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
8. Vorbach C, Harrison R, Capecchi MR. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol. 2003;24:512-517.
9. Pulendran B. Immune activation: Death, danger and dendritic cells. Curr Biol. 2004;4:R30-R32.
10. Jerome KR, Corey L. The danger within. N Engl J Med. 2004;350:411-412.
11. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-1190.
12. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589-606.
13. Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004;20:369-379.
14. Beckman JS, Beckman JS, Parks DA, Pearson JD, Marshall PA, Freeman BA. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Radic Biol Med. 1989;6:607-615.
15. Vorbach C, Scriven A, Capecchi MR. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev. 2002;16:3223-3235.
16. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409.
17. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83:473-482.
18. Norwood VF, Morham SG, Smithies O. Postnatal development and progression of renal dysplasia in cydooxygenase-2 null mice. Kidney Int. 2000;58:2291-2300.
19. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
20. Stubbe J, Jensen BL, Bachmann S, Morsing P, Skott O. Cyclooxygenase-2 contributes to elevated renin in the early postnatal period in rats. Am J Physiol. 2003;284:R1179-R1189.
21. Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood. 1998;91:1769-1776.
22. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41:1287-1293.
23. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB, Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest. 1995;95:1669-1675.
24. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Cancer Res. 1998;58:2323-2327.
25. Spigelman AD, Farmer KC, Oliver S, Nugent KP, Bennett PN, Notarianni LJ, Dobrocky P, Phillips RK. Caffeine phenotyping of cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familiar adenomatous polyposis. Gut. 1995;36:251-254.
26. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803-809.
27. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familiar adenomatous polyposis. N Engl J Med. 1999;342:1946-1952.
28. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Yamagishi M, Kunieda T, Miyatake K. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160:487-492.
29. Barber SR, Champion HC, Bivalacqua TJ, Hyman AL, Kadowitz PJ. Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular bed. Circulation. 2003;108:896-901.
30. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol. 2002;2:126-130.
31. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-360.
32. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78-84.
33. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858-6862.
34. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J. 1986;235:747-754.
35. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000;376:333-337.
36. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, Harrison DG, Fukai T. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol. 2002;22:1402-1408.
37. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003;15:247-254.
38. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-2897.
39. Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605-613.
40. Gonick HC, Rubini ME, Gleason IO, Sommers SC. The Renal Lesion in Gout. Ann Intern Med. 1965;62:667-674.
41. Aslan M, Freeman BA. Oxidases and oxygenases in regulating vascular nitric oxide signaling and inflammatory responses. Immunol Res. 2002;26:107-118.
42. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-521.